mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs In Vivo
Nucleic Acid Therapeutics · 2024
DOI: 10.1089/nat.2024.0027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2024. Verfasst von Sarah Allen und 12 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA. Hauptthemen laut MEDLINE: Huntingtin Protein, Huntington Disease, RNA, Small Interfering, RNA, Messenger. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the first exon of the huntingtin gene ( HTT ). Oligonucleotide therapeutics, such as short interfering RNA (siRNA), reduce levels of huntingtin mRNA and protein in vivo and are considered a viable therapeutic strategy. However, the extent to which they silence huntingtin mRNA in the nucleus is not established. We synthesized siRNA cross-reactive to mouse (wild-type) Htt and human (mutant) HTT in a divalent scaffold and delivered to two mouse models of HD. In both models, divalent siRNA sustained lowering of wild-type Htt , but not mutant HTT mRNA expression in striatum and cortex. Near-complete silencing of both mutant HTT protein and wild-type HTT protein was observed in both models. Subsequent fluorescent in situ hybridization analysis shows that divalent siRNA acts predominantly on cytoplasmic mutant HTT transcripts, leaving clustered mutant HTT transcripts in the nucleus largely intact in treated HD mouse brains. The observed differences between mRNA and protein levels, exaggerated in the case of extended repeats, might apply to other repeat-associated neurological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
- Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Förderung
- NINDS NIH HHS
- NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Allen, S., O'Reilly, D., Miller, R., Sapp, E., Summers, A., Paquette, J., Echeverria Moreno, D., Bramato, B., McHugh, N., Yamada, K., Aronin, N., DiFiglia, M., & Khvorova, A. (2024). mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs In Vivo. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2024.0027
Vancouver
Allen S, O'Reilly D, Miller R, Sapp E, Summers A, Paquette J, et al. mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs In Vivo. Nucleic Acid Therapeutics. 2024. doi:10.1089/nat.2024.0027
BibTeX
@article{Allen2024,
author = {Allen, Sarah and O'Reilly, Daniel and Miller, Rachael and Sapp, Ellen and Summers, Ashley and Paquette, Joseph and Echeverria Moreno, Dimas and Bramato, Brianna and McHugh, Nicholas and Yamada, Ken and Aronin, Neil and DiFiglia, Marian and Khvorova, Anastasia},
title = {mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs In Vivo},
journal = {Nucleic Acid Therapeutics},
year = {2024},
doi = {10.1089/nat.2024.0027}
}
EUVIMED